ArriVent BioPharma's experimental pill furmonertinib failed to meaningfully delay tumor progression compared with chemotherapy in a late-stage trial for first-line lung cancer patients with EGFR exon 20 insertion mutations. The company reported a median progression-free survival of 11 months at the highest dose versus 9.5 months for chemotherapy, a 1.5-month difference that missed statistical significance. ArriVent said it observed a trend toward a survival benefit and no new safety signals, but the miss erased more than half of the company's market value in pre-market trading.
The result is a setback for ArriVent's hopes of competing in a niche but active field. EGFR exon 20 mutations appear in up to 10% of non-small cell lung tumors, and drugmakers have pursued multiple approaches. Johnson & Johnson's Rybrevant remains a marketed option, while Takeda's Exkivity was withdrawn. AstraZeneca recently agreed to pay up to $1.5 billion for rights to a Dizal Pharma therapy, and a Taiho-Cullinan partnership posted a first-line victory that set a higher bar.
ArriVent's strategy had been to offer a pill with a potentially cleaner side-effect profile than intravenous biologics or combination regimens. CEO Bing Yao said the company will evaluate the data to determine next steps. Furmonertinib is already approved in China for certain lung cancers, where it is sold by original developer Allist Pharmaceuticals, but the failed study closes off the larger first-line opportunity ArriVent had sought.